- Home
- CVKD vs LGVN Comparison
CVKD vs LGVN Comparison
Compare CVKD & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- LGVN
- Stock Information
- Founded
- CVKD 2022
- LGVN 2014
- Country
- CVKD United States
- LGVN United States
- Employees
- CVKD N/A
- LGVN N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- CVKD Health Care
- LGVN Health Care
- Exchange
- CVKD Nasdaq
- LGVN Nasdaq
- Market Cap
- CVKD 17.1M
- LGVN 25.9M
- IPO Year
- CVKD 2023
- LGVN 2021
- Fundamental
- Price
- CVKD $15.24
- LGVN $2.09
- Analyst Decision
- CVKD Strong Buy
- LGVN Strong Buy
- Analyst Count
- CVKD 2
- LGVN 2
- Target Price
- CVKD $52.50
- LGVN $8.00
- AVG Volume (30 Days)
- CVKD 59.6K
- LGVN 393.6K
- Earning Date
- CVKD 11-08-2024
- LGVN 11-08-2024
- Dividend Yield
- CVKD N/A
- LGVN N/A
- EPS Growth
- CVKD N/A
- LGVN N/A
- EPS
- CVKD N/A
- LGVN N/A
- Revenue
- CVKD N/A
- LGVN $1,229,000.00
- Revenue This Year
- CVKD N/A
- LGVN $161.78
- Revenue Next Year
- CVKD N/A
- LGVN $8.62
- P/E Ratio
- CVKD N/A
- LGVN N/A
- Revenue Growth
- CVKD N/A
- LGVN 39.34
- 52 Week Low
- CVKD $5.40
- LGVN $0.77
- 52 Week High
- CVKD $32.55
- LGVN $23.90
- Technical
- Relative Strength Index (RSI)
- CVKD 60.90
- LGVN 54.70
- Support Level
- CVKD $11.19
- LGVN $1.76
- Resistance Level
- CVKD $15.93
- LGVN $2.26
- Average True Range (ATR)
- CVKD 1.36
- LGVN 0.12
- MACD
- CVKD 0.23
- LGVN 0.05
- Stochastic Oscillator
- CVKD 61.01
- LGVN 66.00
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.